rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    FBLG
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      FibroBiologics expands patent portfolio to 170 issued patents
      Nov 12Investing.comFBLG
      Join FibroBiologics' Live Investor Webinar: Advancing a Fibroblast-Based Cell Therapy Platform Across Multiple High-Value Indications
      Nov 12Yahoo FinanceFBLG
      FibroBiologics Announces Grant of European Patent for Fibroblast Delivery of Tumor Inhibitory Agents
      Nov 5Yahoo FinanceFBLG
      FibroBiologics presents data on disc disease treatment approach
      Oct 19Investing.comFBLG
      FibroBiologics Presents Preclinical Data on Fibroblast Spheroid-Derived Chondrocyte Spheroids for Degenerative Disc Disease at the North American Spine Society 2026 Annual Meeting
      Oct 19MorningstarFBLG
      FibroBiologics receives Australian patent acceptance for disc treatment
      Oct 14Investing.comFBLG
      FibroBiologics Announces Australian Patent Accepted for Cellular Blend for the Regeneration of Chondrocytes and Cartilage Cells in Degenerated Spinal Discs
      Oct 14Yahoo FinanceFBLG
      FibroBiologics Raises Capital via Convertible Debenture Financing

      Detailed price information for Fibrobiologics Inc (FBLG-Q) from The Globe and Mail including charting and trades.

      Oct 9The Globe and MailFBLG
      FibroBiologics files patent for cell-based peptide delivery
      Oct 7Investing.comFBLG
      EXCLUSIVE: FibroBiologics Files Patent Application For Cell-Based Alternative to GLP-1 Injections - Fibro

      FibroBiologics files a U.S. patent application for engineered cell technology designed to supply continuous GLP-1 therapy internally.

      Oct 7BenzingaFBLG
      EXCLUSIVE: FibroBiologics Files Patent Application For Cell-Based Alternative to GLP-1 Injections
      Oct 7Yahoo FinanceFBLG
      FibroBiologics Files Patent Application for Technology Designed to Produce GLP-1 and Other Therapeutic Peptides Inside the Body
      Oct 7Yahoo FinanceFBLG
      Fibrobiologics Inc (FBLG-Q) Statistics

      Find out all the key statistics for Fibrobiologics Inc (FBLG-Q), including valuation measures, fiscal year financial statistics, trading record, share statistics and more.

      Oct 2The Globe and MailFBLG
      FibroBiologics receives European patent for fibroblast therapy
      Sep 29Investing.comFBLG
      FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity
      Sep 29MorningstarFBLG
      Nova Minerals and FibroBiologics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

      ORLANDO, FL / ACCESS Newswire / September 25, 2026 / RedChip Companies will air interviews with Nova Minerals Corp (NYSE American:NVA)(ASX:NVA) and FibroBiologics, Inc. (NASDAQ:FBLG) on the RedChip Small Stocks, Big Money™ show, a sponsored television program airing on Bloomberg TV this Saturday, September 26, at 7:00 p.

      Sep 25Yahoo FinanceNVAFBLG
      FibroBiologics Shareholders Approve Potential Warrant-Driven Share Issuance

      Detailed price information for Fibrobiologics Inc (FBLG-Q) from The Globe and Mail including charting and trades.

      Sep 19The Globe and MailFBLG
      FibroBiologics CSO invests $500,000 in private placement By Investing.com
      Sep 17Investing.comFBLG
      FibroBiologics Announces Closing of $0.5 Million Private Placement with Chief Scientific Officer
      Sep 17MorningstarFBLG
      FibroBiologics Announces Insider Private Placement Financing

      Detailed price information for Fibrobiologics Inc (FBLG-Q) from The Globe and Mail including charting and trades.

      Sep 16The Globe and MailFBLG
      Join FibroBiologics' Live Investor Webinar: Advancing a Fibroblast-Based Cell Therapy Platform Across Multiple High-Value Indications

      The exclusive event will feature Pete O'Heeron, CEO, and Jason Davis, CFO, who will provide an overview of FibroBiologics' strategy to develop off-the-shelf fibroblast-based cell therapies for chronic diseases and regenerative medicine. The Company is advancing a platform designed to harness the regenerative and immune-modulating properties of fibroblasts across multiple indications, including chronic wound care, psoriasis, multiple sclerosis, degenerative disc disease, and thymus regeneration.

      Sep 8Yahoo FinanceFBLG
      FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing

      FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,721,866, titled "Therapeutic Use of Fibroblasts for Use in Wound Healing." The patent, issued on September 1, 2026, covers

      Sep 3Yahoo FinanceFBLG
      FibroBiologics Announces Issuance of New U.S. Patent for the Treatment of Degenerative Disc Disease Using Fibroblast Conditioned Media
      Sep 1MorningstarFBLG
      FibroBiologics Releases Third Batch of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
      Aug 27MorningstarFBLG
      FibroBiologics ships third batch of trial drug to Australia
      Aug 27Investing.comFBLG
      FibroBiologics advances diabetic ulcer trial with new drug shipment to Australia

      FibroBiologics (NASDAQ:FBLG), a clinical-stage biotechnology company, has released and shipped the third batch of its experimental drug product, CYWC628, to Australia to support an ongoing clinical trial for diabetic foot ulcers (DFUs). The compant describes the investigational treatment as a...

      Aug 27Yahoo FinanceFBLG
      FibroBiologics Regains Compliance with Nasdaq Trading Rules
      Aug 26MorningstarFBLG
      FibroBiologics regains Nasdaq bid price compliance
      Aug 26Investing.comFBLG
      FibroBiologics Adds Leigh Steinberg to Board for Growth

      Tipranks Press Release.

      Aug 25The Globe and MailFBLG
      FibroBiologics appoints Leigh Steinberg to board
      Aug 24Investing.comFBLG
      FibroBiologics Appoints Leigh Steinberg to Board of Directors

      FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the appointment of Leigh Steinberg to its Board of Directors. Widely regarded as the most influential sports agent of his generation, Mr. Steinberg brings five decades of dealmaking experience, a deep commitment

      Aug 24Yahoo FinanceFBLG

      This is the newest page. Registered accounts read further back.